查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1800891

2025 年至 2033 年青光眼治疗市场报告（按药物类别、适应症、最终用户和地区划分）

Glaucoma Therapeutics Market Report by Drug Class, Indication, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球青光眼治疗市场规模达84亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到141亿美元，2025-2033年期间的复合年增长率（CAGR）为5.35%。北美目前占据市场领先地位，这得益于其先进的医疗基础设施、日益​​提升的认知度、尖端治疗手段的可及性、强有力的监管支持以及大量面临青光眼风险的老龄人口。全球青光眼盛行率的不断上升、早期诊断技术的不断进步、眼科远距医疗的日益普及以及外科手术领域的众多技术创新，这些都是推动市场发展的一些因素。

青光眼是全球永久性失明的主要原因之一，每年确诊的人数都在增加。此疾病通常进展缓慢且无症状，这使得早期发现更加困难，导致需要持续治疗的患者群体更大，从而拓宽了青光眼治疗市场。此外，公众意识的提升和青光眼相关教育的加强，正在促使更多人接受筛检，从而实现更早的发现。早期介入导致治疗需求增加，因为患者希望在视神经严重受损之前控制病情，从而支持市场成长。此外，製药公司和医疗机构对研究计画的投入不断增加，也促使新疗法的发现，包括专注于维护视神经健康的神经保护疗法。这种对创新的重视带来了更多的治疗选择，从而拓宽了市场供应，并为患者有效控制青光眼带来了新的希望。

青光眼治疗市场趋势/驱动因素：

外科手术的进步

外科技术的进步正在影响青光眼治疗市场，尤其是微创青光眼手术 (MIGS) 的兴起。 MIGS 为青光眼的治疗带来了革命性的变化，它提供了更安全的替代方案，相比传统手术，并发症更少、恢復期更短、操作更简单。这项进步为外科医生提供了更多治疗选择，同时降低了患者的风险和不适感。此外，包括微支架和创新引流系统在内的手术器械的进步也正在提高青光眼手术的疗效。一个重要的创新案例是爱尔康于2025年在美国推出的 Voyager™ DSLT，这是首款全自动直接选择性雷射小梁成形术 (SLT) 设备。该设备无需使用角膜镜或手动瞄准，即可提供120个雷射脉衝，从而简化了 SLT 手术流程，提高了准确性并最大限度地降低了手术复杂性。这些技术创新增强了人们对外科手术的信任，促进了市场扩张并提高了治疗效果。

仿製药的成长

仿製药青光眼药物的日益普及，为更多患者提供了经济有效的治疗方案。前列腺素类似物等知名青光眼药物的仿製药，在保持其有效性的同时，为品牌药物提供了一种经济实惠的替代品。这一趋势对于提高治疗可及性至关重要，尤其对于那些可能面临财务困难或保险覆盖受限的患者而言。仿製药有助于降低医疗费用，同时使更广泛的患者群体能够获得有效的青光眼治疗。随着越来越多的製药公司推出知名药物的仿製药，竞争愈演愈烈，从而导致价格下降和市场准入的扩大。 2024年，美国Glenmark Pharmaceuticals Inc.推出了Travatan Z-Travoprost眼药水0.004%的仿製药，用于治疗青光眼和眼高压。该产品与山德士的参考药物生物等效，并扩展了Glenmark的眼科产品组合。截至 2024 年 9 月，Travatan Z 在美国的年销售额达到 6,620 万美元。

基因治疗的进展

基因治疗的最新进展为治疗青光眼提供了新颖且富有创意的方法。科学家正在研究旨在解决青光眼根本原因的基因疗法，例如保护视网膜神经节细胞和改善粒线体功能。这些疗法涉及将特定基因导入眼部，旨在降低眼压，同时保护视神经完整性并增强视觉相关细胞的整体功能。随着基因疗法在临床试验中的进展，它有望成为传统疗法的替代疗法，并可能带来持久的优势和更少的副作用。这些先进疗法的研发吸引了大量投资和关注，透过为患者提供更精准、更有效的青光眼控制选择，推动了市场扩张。 2024年，都柏林圣三一学院的研究人员宣布了一种突破性的青光眼基因疗法，该疗法可以保护视网膜神经节细胞并增强粒线体功能。该疗法使用腺相关病毒（AAV）递送的eNdi1基因，在动物和人类模型中改善了视觉相关细胞的功能。成立了一家分拆公司 Vzarii Therapeutics，以推动其进入临床试验阶段。

青光眼治疗市场的成长动力：

老年人口不断增加

全球老龄人口不断增长，尤其是在已开发国家和快速发展的国家，导致青光眼病例大幅增加。世界卫生组织 (WHO) 估计，到 2030 年，全球每六人中就有一人年龄在 60 岁或以上，预计到 2050 年这一数字将翻一番，达到 21 亿。这种人口结构变化导致青光眼易感患者数量增加，对有效的诊断方法、替代治疗方法和持续管理方案的需求日益增长。老年人更容易患青光眼等长期疾病，通常需要持续治疗以避免视力受损。因此，老年人口的不断增长推动了对新疗法的需求，包括药物和手术治疗。这一趋势鼓励对研发投入，以製定满足老年患者独特需求的客製化疗法，从而进一步促进市场成长。

提高认识和早期诊断

提高人们对青光眼的认识对于刺激青光眼治疗市场扩张至关重要。健康运动、眼科护理组织的努力以及资讯的普及都有助于提高人们对青光眼的认识。随着越来越多的人认识到早期发现的重要性，对常规眼科检查的需求也在增加，尤其是在高风险族群中。早期诊断可以及时干预，降低不可逆视力丧失的风险，并确保更好的治疗效果。 2024年，艾伯维印度公司和Sightsavers印度公司发起了一项为期15个月的活动，以提高人们对青光眼的认识，并专注于40岁及以上的人。该计划包括筛检营、线上推广和教育项目，以鼓励早期诊断和治疗。这种向积极主动医疗保健的转变导致对青光眼药物、诊断工具和手术治疗的需求增加。因此，更高的认识直接推动了青光眼疗法的采用。

药物输送系统的进展

缓释植入物、泪点塞和注射等创新技术正在改变青光眼的治疗方式。这些创新系统比传统的眼药水俱有更持久的药效，因为传统的眼药水需要定期使用，这常常导致患者依从性不足。例如，缓释系统可以提供数週甚至数月的药物，最大限度地减少每日给药的必要性，并提高治疗依从性。这不仅提高了患者的舒适度，还保证了均匀的治疗效果，最终实现更卓越的眼压管理。对增强药物传递系统的高度重视，正在催化对更先进的青光眼疗法的需求。 2024年，Ripple Therapeutics宣布与AbbVie合作开发RTC-620，这是一种完全可生物降解的缓释前房植入物，用于降低青光眼患者的眼压。 Ripple将负责临床前开发，而AbbVie将领导临床试验和商业化。该植入物允许重复给药，无需使用聚合物或赋形剂，从而降低发炎风险。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球青光眼治疗市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依药品类别

  • 前列腺素类似物
  • β受体阻断剂
  • α肾上腺素激动剂
  • 碳酸酐酶抑制剂
  • 联合用药
  • 其他的

第七章：市场区隔：依指标

  • 开角型青光眼
  • 闭角型青光眼
  • 其他的

第八章：市场区隔：按最终用户

  • 医院
  • 眼科诊所
  • 门诊手术中心
  • 其他的

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十章：SWOT分析

第 11 章：价值链分析

第 12 章：波特五力分析

第十三章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Aerie Pharmaceuticals Inc.
    • Allergan Plc
    • Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
    • Inotek Pharmaceuticals Corp.
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Santen Pharmaceutical Co. Ltd.
    • SIFI SpA
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112025A2770

The global glaucoma therapeutics market size reached USD 8.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 14.1 Billion by 2033, exhibiting a growth rate (CAGR) of 5.35% during 2025-2033. North America currently leads the market because of advanced healthcare infrastructure, increasing awareness, access to cutting-edge treatments, strong regulatory support, and a large aging population at risk for glaucoma. The growing prevalence of glaucoma across the globe, continual advancements in diagnostic technologies for early detection, the rising adoption of telemedicine in ophthalmology, and numerous technological innovations in surgical procedures represent some of the factors that are propelling the market.

Glaucoma ranks among the top causes of permanent blindness globally, with a growing number of individuals being diagnosed annually. The condition typically advances gradually and asymptomatically, complicating early detection and resulting in a larger group of patients needing continuous therapeutic care, thereby broadening the market for glaucoma treatments. Moreover, increasing public awareness initiatives and better education regarding glaucoma are motivating more individuals to undergo screenings, resulting in earlier detections. Earlier intervention leads to an increase in the need for therapeutic treatments as patients aim to control the disease prior to substantial optic nerve damage, supporting the market growth. Besides this, heightened funding from pharmaceutical firms and healthcare institutions in research operations is leading to the identification of new therapies, including neuroprotective treatments focused on maintaining optic nerve health. This emphasis on innovation leads to additional treatment choices, thereby broadening the market offerings and providing patients with renewed optimism for effectively managing glaucoma.

Glaucoma Therapeutics Market Trends/Drivers:

Advancements in Surgical Procedures

Advancements in surgical technology are influencing the glaucoma therapeutics market, especially with the emergence of minimally invasive glaucoma surgeries (MIGS). MIGS is revolutionizing the treatment of glaucoma by providing safer alternatives with reduced complications, quicker recovery periods, and simpler procedures in contrast to conventional surgeries. This advancement provides surgeons with additional treatment options while reducing risks and discomfort for patients. Moreover, developments in surgical instruments, including micro-stents and innovative drainage systems, are improving the effectiveness of glaucoma surgeries. A significant instance of innovation is the 2025 introduction of Alcon's Voyager(TM) DSLT in the US, the initial fully automated Direct Selective Laser Trabeculoplasty apparatus. This instrument streamlines the SLT process by providing 120 laser pulses without requiring a gonio lens or manual targeting, enhancing accuracy and minimizing procedural intricacy. These technological innovations enhance trust in surgical procedures, boosting market expansion and enhancing treatment results.

Growth of Generic Drugs

The increasing availability of generic glaucoma drugs is providing more access to cost-effective therapies. Generic forms of well-known glaucoma medications, like prostaglandin analogs, offer an economical substitute to name-brand treatments while maintaining their effectiveness. This trend is essential for increasing access to treatment, especially for patients who might face financial limitations or restrictions in insurance coverage. Generic medications contribute to lower healthcare expenses while allowing a wider patient demographic to gain access to effective treatments for glaucoma. With the rise of pharmaceutical companies launching generic versions of well-known medications, competition intensifies, leading to lower prices and broader market access. In 2024, Glenmark Pharmaceuticals Inc., USA launched a generic version of Travatan Z-Travoprost ophthalmic solution 0.004%-for treating glaucoma and ocular hypertension. The product is bioequivalent to Sandoz's reference drug and expands Glenmark's ophthalmic portfolio. Travatan Z recorded $66.2 million in annual U.S. sales as of September 2024.

Advancements in Gene Therapy

Recent advancements in gene therapy are providing novel, creative methods for addressing the condition. Scientists are investigating gene therapies aimed at addressing the root causes of glaucoma, such as the protection of retinal ganglion cells and the improvement of mitochondrial functions. These treatments, which involve introducing particular genes to the eye, seek to reduce intraocular pressure while also protecting optic nerve integrity and enhancing the overall function of vision-related cells. With the advancement of gene therapy in clinical trials, it emerges as a hopeful substitute for conventional treatments and may provide lasting advantages with reduced side effects. The creation of these advanced treatments is drawing considerable investment and focus, driving market expansion by offering patients more precise, efficient choices for controlling glaucoma. In 2024, Trinity College Dublin researchers announced a breakthrough gene therapy for glaucoma that protects retinal ganglion cells and enhances mitochondrial function. The therapy, using an AAV-delivered eNdi1 gene, improved vision-related cell performance in animal and human models. A spinout, Vzarii Therapeutics, was formed to advance it toward clinical trials.

Glaucoma Therapeutics Market Growth Drivers:

Growing Geriatric Population

The increasing elderly population worldwide, especially in advanced and swiftly developing nations, is leading to a significant rise in glaucoma cases. The World Health Organization (WHO) estimates that by 2030, one in every six individuals globally will be 60 years or older, a figure anticipated to double by 2050, hitting 2.1 billion. This demographic change is expanding the number of patients vulnerable to glaucoma, leading to a growing need for effective diagnostic methods, treatment alternatives, and continuous management approaches. Senior individuals are more vulnerable to long-term ailments such as glaucoma, which frequently necessitates ongoing treatment to avert vision impairment. Therefore, the rising number of elderly individuals is driving the demand for new treatments, including both medical and surgical options. This trend is encouraging investment in research operations to formulate customized therapies that meet the unique requirements of elderly patients, further bolstering the market growth.

Rising Awareness and Early Diagnosis

Raising awareness regarding glaucoma is crucial for stimulating the expansion of the glaucoma therapeutics market. Health campaigns, efforts by eye-care organizations, and greater information accessibility are all helping to raise awareness about the condition. With an increasing number of people recognizing the significance of early detection, there is a rise in the demand for routine eye examinations, especially among high-risk groups. Early diagnosis allows for timely intervention, reducing the risk of irreversible vision loss and ensuring better treatment outcomes. In 2024, AbbVie India and Sightsavers India initiated a 15-month campaign to raise awareness about glaucoma, focusing on people aged 40 and older. The initiative featured screening camps, online outreach, and educational programs to encourage early diagnosis and treatment. This shift towards proactive healthcare leads to higher demand for glaucoma medications, diagnostic tools, and surgical treatments. As a result, greater awareness is directly driving the adoption of glaucoma therapies.

Advancements in Drug Delivery Systems

Innovations, such as sustained-release implants, punctal plugs, and injectable formulations, are changing how glaucoma treatments are delivered. These innovative systems offer a more enduring effect than conventional eye drops, which necessitate regular application, frequently resulting in insufficient patient adherence. Sustained-release systems, for instance, can provide medication for weeks or even months, minimizing the necessity for daily administration and enhancing treatment compliance. This not only improves patient comfort but also guarantees uniform therapeutic outcomes, ultimately resulting in superior management of intraocular pressure. The heightened emphasis on enhancing drug delivery systems is catalyzing the demand for more sophisticated glaucoma therapies. In 2024, Ripple Therapeutics announced a collaboration with AbbVie to develop RTC-620, a fully biodegradable sustained-release intracameral implant for reducing intraocular pressure in glaucoma. Ripple will handle preclinical development, while AbbVie will lead clinical trials and commercialization. The implant allowed repeat dosing without polymers or excipients, reducing inflammation risk.

Glaucoma Therapeutics Industry Segmentation:

Breakup by Drug Class:

  • Prostaglandin Analogs
  • Beta Blockers
  • Alpha Adrenergic Agonists
  • Carbonic Anhydrase Inhibitors
  • Combination Drugs
  • Others

Prostaglandin analogs represents the largest market segment

The prostaglandin analogs segment in the market is predominantly driven by their efficacy in reducing intraocular pressure with fewer systemic side effects compared to other classes of glaucoma medications. The once-daily dosing convenience of these drugs also contributes to patient compliance, thereby increasing its market demand. Innovation in formulations and delivery mechanisms is another major factor contributing to its market share. Intellectual property expiry and subsequent entry of generics, however, pose a challenge to market growth. Lastly, their versatile compatibility with other classes of glaucoma medications makes them a preferred choice in combination therapies, bolstering the segment's prominence.

On the other hand, the beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, combination drugs and other segments are influenced by a diverse range of factors such as affordability, varied mechanisms of action, and well-established safety profiles. These drugs are often prescribed in cases where Prostaglandin Analogs are contraindicated or not effective. Despite their efficacy, the need for multiple daily dosing can impact patient compliance. Availability of generics in this category also makes it a cost-effective option for treatment.

Breakup by Indication:

  • Open Angle Glaucoma
  • Angle Closure Glaucoma
  • Others

Open angle glaucoma represents the largest market segment

The open-angle glaucoma segment is primarily fueled by its prevalence, constituting the majority of glaucoma cases globally. Increased awareness and advancements in diagnostic techniques have led to earlier and more frequent detection of this condition. The availability of multiple treatment options, ranging from medications to surgeries, offers a comprehensive approach to managing open-angle glaucoma. Aging demographics further amplify the incidence rates, thereby driving glaucoma therapeutics market demand. Government initiatives aimed at eye health contribute to the overall market growth for this segment.

On the other hand, the growth in angle closure glaucoma and other segments is primarily driven by an aging population, as the condition is more prevalent among older adults. Advances in diagnostic technologies have also contributed to the segment's expansion by enabling earlier and more accurate detection of the condition. In addition, the increased awareness about the severity of untreated angle-closure glaucoma, which can lead to blindness, has led to higher demand for effective treatments.

Breakup by End User:

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgery Centers
  • Others

Hospitals accounts for the majority of the market share

Hospitals are major consumers in the glaucoma therapeutics market, given their capability to offer advanced diagnostic and surgical interventions. The consolidation of healthcare facilities and investment in state-of-the-art ophthalmic departments contribute to the segment's growth. Additionally, hospitals are often the first point of contact for emergency eye conditions, thereby positioning them as crucial stakeholders. Public and private insurance coverages also incentivize treatment in hospital settings, increasing patient throughput and consumption of glaucoma medications.

On the other hand, the growth in ophthalmic clinics, ambulatory surgery centers, and other segments can be attributed to the specialized focus on eye care, the availability of advanced diagnostic equipment, and faster patient turnover. Increasing consumer preference for specialized care is also a contributing factor. Decentralization of healthcare services and the expansion of ambulatory surgery centers make these settings accessible for minor procedures and regular check-ups. The growth is further supported by flexible payment options and shorter waiting times.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest glaucoma therapeutics market share

The glaucoma therapeutics market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The market in the North America region is significantly impelled by high healthcare expenditure, robust insurance frameworks, and the presence of leading pharmaceutical companies are primary drivers. Furthermore, the region is home to a diverse and aging population, thereby creating a natural demand for glaucoma treatments. Technological advancements in drug formulation and delivery, backed by substantial investments in research and development, also fuel glaucoma therapeutics market growth.

Regulatory support in terms of expedited approvals and grants fosters innovation, providing a favorable environment for market expansion. Government initiatives in healthcare education and eye screenings contribute to early diagnosis and, in turn, drive demand for therapeutics. Accessibility to specialty ophthalmic clinics and ambulatory surgery centers adds another layer of convenience, encouraging timely intervention.

The availability of both branded and generic drugs offers options across various price points, catering to a wide consumer base. Furthermore, collaborations between public and private sectors in healthcare initiatives serve to increase awareness as well as facilitate entry and acceptance of novel therapeutic solutions in the market.

Competitive Landscape:

The major players in the market are persistently working to develop more effective and less invasive treatment options. They are investing heavily in clinical trials to produce medicines and devices that provide longer-lasting relief with fewer side effects. Collaborations with research institutions and healthcare organizations are common strategies these key players are adopting. Market leaders are also expanding their portfolios by launching innovative products specifically designed to manage different types of glaucoma. Furthermore, these companies are working diligently to meet stringent regulatory requirements, ensuring that their products are both safe and effective. Furthermore, they are also focusing on patient education and awareness programs as a part of their market expansion strategies, thereby offering a favorable glaucoma therapeutics market outlook.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Aerie Pharmaceuticals Inc.
  • Allergan Plc
  • Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
  • Inotek Pharmaceuticals Corp.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Santen Pharmaceutical Co. Ltd.
  • SIFI S.p.A
  • Teva Pharmaceutical Industries Ltd

Key Questions Answered in This Report

  • 1.How big is the global glaucoma therapeutics market?
  • 2.What is the expected growth rate of the global glaucoma therapeutics market during 2025-2033?
  • 3.What are the key factors driving the global glaucoma therapeutics market?
  • 4.What has been the impact of COVID-19 on the global glaucoma therapeutics market?
  • 5.What is the breakup of the global glaucoma therapeutics market based on the drug class?
  • 6.What is the breakup of the global glaucoma therapeutics market based on the indication?
  • 7.What is the breakup of the global glaucoma therapeutics market based on the end user?
  • 8.What are the key regions in the global glaucoma therapeutics market?
  • 9.Who are the key players/companies in the global glaucoma therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Glaucoma Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Prostaglandin Analogs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Beta Blockers
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alpha Adrenergic Agonists
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Carbonic Anhydrase Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Combination Drugs
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Open Angle Glaucoma
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Angle Closure Glaucoma
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ophthalmic Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Ambulatory Surgery Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Aerie Pharmaceuticals Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Allergan Plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Inotek Pharmaceuticals Corp.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Merck & Co. Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Novartis AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Pfizer Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Santen Pharmaceutical Co. Ltd.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 SIFI S.p.A
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Glaucoma Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Glaucoma Therapeutics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Glaucoma Therapeutics Market: Breakup by Drug Class (in %), 2024
  • Figure 4: Global: Glaucoma Therapeutics Market: Breakup by Indication (in %), 2024
  • Figure 5: Global: Glaucoma Therapeutics Market: Breakup by End User (in %), 2024
  • Figure 6: Global: Glaucoma Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 7: Global: Glaucoma Therapeutics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 8: Global: Glaucoma Therapeutics (Prostaglandin Analogs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Glaucoma Therapeutics (Prostaglandin Analogs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Glaucoma Therapeutics (Beta Blockers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Glaucoma Therapeutics (Beta Blockers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Glaucoma Therapeutics (Alpha Adrenergic Agonists) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Glaucoma Therapeutics (Alpha Adrenergic Agonists) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Glaucoma Therapeutics (Carbonic Anhydrase Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Glaucoma Therapeutics (Carbonic Anhydrase Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Glaucoma Therapeutics (Combination Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Glaucoma Therapeutics (Combination Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Glaucoma Therapeutics (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Glaucoma Therapeutics (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Glaucoma Therapeutics (Open Angle Glaucoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Glaucoma Therapeutics (Open Angle Glaucoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Glaucoma Therapeutics (Angle Closure Glaucoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Glaucoma Therapeutics (Angle Closure Glaucoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Glaucoma Therapeutics (Other Indications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Glaucoma Therapeutics (Other Indications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Glaucoma Therapeutics (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Glaucoma Therapeutics (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Glaucoma Therapeutics (Ophthalmic Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Glaucoma Therapeutics (Ophthalmic Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Glaucoma Therapeutics (Ambulatory Surgery Centers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Glaucoma Therapeutics (Ambulatory Surgery Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Glaucoma Therapeutics (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Glaucoma Therapeutics (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: North America: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: North America: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: United States: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: United States: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Canada: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Canada: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Asia Pacific: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Asia Pacific: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: China: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: China: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Japan: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Japan: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: India: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: India: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: South Korea: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: South Korea: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Australia: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Australia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Indonesia: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Indonesia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Others: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Europe: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Europe: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Germany: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Germany: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: France: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: France: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: United Kingdom: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: United Kingdom: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Italy: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Italy: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Spain: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Spain: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Russia: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Russia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Others: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Latin America: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Latin America: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Brazil: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Brazil: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Mexico: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Mexico: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Others: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Middle East and Africa: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Middle East and Africa: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Global: Glaucoma Therapeutics Industry: SWOT Analysis
  • Figure 83: Global: Glaucoma Therapeutics Industry: Value Chain Analysis
  • Figure 84: Global: Glaucoma Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Glaucoma Therapeutics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Glaucoma Therapeutics Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 3: Global: Glaucoma Therapeutics Market Forecast: Breakup by Indication (in Million USD), 2025-2033
  • Table 4: Global: Glaucoma Therapeutics Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Glaucoma Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Glaucoma Therapeutics Market: Competitive Structure
  • Table 7: Global: Glaucoma Therapeutics Market: Key Players